PT  - JOURNAL ARTICLE
AU  - Sebastian Bruno Ulrich Jordi
AU  - Brian Matthew Lang
AU  - Bianca Auschra
AU  - Roland von Känel
AU  - Luc Biedermann
AU  - Thomas Greuter
AU  - Philipp Schreiner
AU  - Gerhard Rogler
AU  - Niklas Krupka
AU  - Michael Christian Sulz
AU  - Benjamin Misselwitz
AU  - Stefan Begré
AU  - on behalf of the Swiss IBD cohort study group
TI  - Depressive symptoms and single nucleotide polymorphisms predict clinical recurrence of inflammatory bowel disease
AID  - 10.1101/2020.06.29.20139030
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.29.20139030
4099  - http://medrxiv.org/content/early/2020/06/30/2020.06.29.20139030.short
4100  - http://medrxiv.org/content/early/2020/06/30/2020.06.29.20139030.full
AB  - Background and Aims Inflammatory bowel disease (IBD) patients are at high risk for depression. We examined interrelations between genetic risk factors for depression, depressive symptoms and IBD flares.Methods In 1973 patients (1137 Crohn’s disease, 836 ulcerative colitis) of the Swiss IBD cohort study (SIBDC), 62 single nucleotide polymorphisms (SNPs) preselected for associations with depression, stress, pain and smoking were screened for cross-sectional associations with depression (hospital anxiety and depression subscale for depression, HADS-D≥11). Logistic regression and Cox proportional hazards models were built to test for effects of depressive symptoms on disease course and genetic risk factors on depression and disease course. As endpoints we used active disease (CDAI≥150 or MTWAI≥10) and two published composite flare definitions: FNCE: physician reported flare, non-response to therapy, new complication or extraintestinal manifestation and AFFSST: active disease, physician reported flare, fistula, stenosis and new systemic therapy.Results Depressive symptoms were a strong risk factor for disease related endpoints including active disease (adjusted hazard ratio, aHR: 3.25, p<0.001), AFFSST (aHR: 1.62, p<0.001) and FNCE (aHR: 1.35, p=0.019). Rs588765’s TC alleles and rs2522833’s C allele were associated with depressive symptoms at baseline (odds ratio, OR: 0.43, q=0.050 and OR: 1.73, q=0.059, respectively). Rs588765-TC remained protective regarding presence of depression (aHR: 0.67, p=0.035) and was associated with fewer active disease states (aHR: 0.72, p=0.045) during follow-up.Conclusions In IBD, genetics, depressive symptoms and inflammatory activity are intimately related: Depressive symptoms were a predictor of clinical deterioration and rs588765-TC was protective for depression and high IBD activity.Funding This work was supported by the Swiss National Science Foundation (SNSF).Competing Interest StatementS.B.U.J., B.M.L., B.A., N.K. and S.B. have nothing to disclose. R.v.K. has served at an advisory board of Vifor AG, Switzerland unrelated to this work. L.B. reports fees for consulting/advisory board from Abbvie, MSD, Vifor, Falk, Esocap, Calypso, Ferring, Pfizer, Shire, Takeda, Janssen, Ewopharma. TG has consulting contracts with Sanofi-Regeneron and Falk Pharma GmbH, received travel grants from Falk Pharma GmbH and Vifor, and an unrestricted research grant from Novartis. P.S. reports consultant fees from Pfizer, Takeda and Janssen-Cilag. G.R. has consulted to Abbvie, Augurix, BMS, Boehringer, Calypso, Celgene, FALK, Ferring, Fisher, Genentech, Gilead, Janssen, MSD, Novartis, Pfizer, Phadia, Roche, UCB, Takeda, Tillots, Vifor, Vital Solutions and Zeller; G.R. has received speaker's honoraria from Astra Zeneca, Abbvie, FALK, Janssen, MSD, Pfizer, Phadia, Takeda, Tillots, UCB, Vifor and Zeller; G.R. has received educational grants and research grants from Abbvie, Ardeypharm, Augurix, Calypso, FALK, Flamentera, MSD, Novartis, Pfizer, Roche, Takeda, Tillots, UCB and Zeller. M.C.S. has received consultant and/or speaker fees from Abbvie, Ferring, MSD, Janssen, Pfizer, Takeda, UCB. B.M. has served at an advisory board for Gilead and Novigenix. He has received speaking fees from Vifor, MSD and Takeda and traveling fees from Vifor, Novartis, MSD and Takeda. BM has received a research grant from MSD unrelated to this work.Funding StatementThis work was supported by the Swiss National Science Foundation (SNSF), [grant number 33CS30-148422 to G.R.].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review board approval No. EK-1316, approved on February 5, 2007 and KEK Zurich, March 9, 2020; BASEC 2018-02068. Analysis of patient data for this study was approved by the scientific board of SIBDCS.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available and in possession of the corresponding author.aHRadjusted hazard ratioAICAkaike information criterionBMIbody mass indexCDCrohn’s diseaseCDAICrohn’s Disease Activity IndexCHRNA5cholinergic receptor nicotinic alpha 5 subunitCIconfidence intervalEIMextraintestinal manifestationsENSenteric nervous systemHADSHospital Anxiety and Depression ScaleHRhazard ratioIBDinflammatory bowel diseaseICindeterminate colitisLDlinkage disequilibriumMTWAIModified Truelove and Witts Severity IndexNAChRnicotinic acetylcholine receptorsORodds ratioPCLOpiccolo presynaptic cytomatrix proteinPSCprimary sclerosing cholangitisR2square of the correlation coefficientSIBDCSwiss IBD cohortSNPsingle nucleotide polymorphismtnfollow-up time n of recordingTNFtumor necrosis factorUCulcerative colitis